The U.S. Supreme Court opens its new term this week with a challenge that could have profound business implications for patent holders and those who pay them for licenses to use the patents in developing their own products.
The justices this term continue their heightened interest in the development of patent law by agreeing thus far to decide two patent challenges: MedImmune v. Genentech, No. 05-608, and KSR International v. Teleflex, No. 04-1350.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
